**Sonoma Pharmaceuticals Expands U.S. Cosmetic Market Access with FDA MoCRA Registration** BOULDER, COLORADO - Sonoma Pharmaceuticals Inc. (Nasdaq: SNOA), a leading developer of stabilized hypochlorous acid (HOCl) products, announced it has successfully registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA). This regulatory milestone allows Sonoma to manufacture and commercialize its Microcyn technology products as cosmetics in the United States, expanding its reach in the rapidly growing U.S. skincare and dermatology markets. The registration builds on Sonoma's existing FDA medical device establishment registration. No grant or funding was reported; the regulatory approval pertains solely to Sonoma Pharmaceuticals.